Prevalence of metabolic syndrome in a population served by assertive community treatment teams: a retrospective chart review
Authors Fairbairn J, Munshi T, Naeem F, Baldock J, Feakins M
Received 9 November 2017
Accepted for publication 4 July 2018
Published 1 November 2018 Volume 2018:10 Pages 15—19
Checked for plagiarism Yes
Review by Single-blind
Peer reviewer comments 2
Editor who approved publication: Professor Ming-Hui Zou
Jonathan Fairbairn,1 Tariq Munshi,1 Farooq Naeem,2 Jane Baldock,1 Martin Feakins1
1Department of Psychiatry, Queen’s University, Kingston, ON, Canada; 2Department of Psychiatry, University of Toronto, Toronto, ON, Canada
Background: Metabolic syndrome (MetS) is defined as the co-occurrence of risk factors for both type 2 diabetes and cardiovascular disease. This includes abdominal obesity, hyperglycemia, dyslipidemia, and hypertension. MetS is associated with significant morbidity and mortality from cardiovascular events and from all-cause mortality. MetS occurs at a higher rate in patients with serious mental illness compared to the general population.
Methods: A retrospective chart review was performed to determine the MetS prevalence and antipsychotic prescribing patterns for patients followed by 2 assertive community treatment teams (ACTTs; n=59). MetS criteria including blood pressure, body mass index, waist circumference, fasting cholesterol, and fasting blood sugar levels were extracted. Additional information including patient demographics, psychiatric diagnosis, and prescription medications were also collected and analyzed.
Results: The prevalence of the MetS among ACTT patients was 52.5%. The use of the metabolically favorable antipsychotic aripiprazole (n=10) remains limited in this population. There were no patients in this sample who were prescribed ziprasidone, lurasidone, or asenapine, all of which are associated with limited metabolic side effects.
Conclusion: MetS is prevalent among patients with severe and persistent mental illness followed by ACTTs. Despite the high rate of MetS in this patient population, the use of antipsychotics with favorable metabolic profiles remains limited.
Keywords: metabolic syndrome, atypical antipsychotics, severe and persistent mental illness
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]